» Articles » PMID: 11895781

CD4(+) and CD8(+) Anergic T Cells Induced by Interleukin-10-treated Human Dendritic Cells Display Antigen-specific Suppressor Activity

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2002 Mar 16
PMID 11895781
Citations 137
Authors
Affiliations
Soon will be listed here.
Abstract

Interleukin-10 (IL-10)-treated dendritic cells (DCs) induce an alloantigen- or peptide-specific anergy in various CD4(+) and CD8(+) T-cell populations. In the present study, we analyzed whether these anergic T cells are able to regulate antigen-specific immunity. Coculture experiments revealed that alloantigen-specific anergic CD4(+) and CD8(+) T cells suppressed proliferation of syngeneic T cells in a dose-dependent manner. The same effect was observed when the hemagglutinin-specific CD4(+) T-cell clone HA1.7 or tyrosinase-specific CD8(+) T cells were cocultured with anergic T cells of the same specificity. Anergic T cells did not induce an antigen-independent bystander inhibition. Suppression was dependent on cell-to-cell contact between anergic and responder T cells, required activation by antigen-loaded DCs, and was not mediated by supernatants of anergic T cells. Furthermore, anergic T cells displayed an increased extracellular and intracellular expression of cytotoxic T-lymphocyte antigen (CTLA)-4 molecules, and blocking of the CTLA-4 pathway restored the T-cell proliferation up to 70%, indicating an important role of the CTLA-4 molecule in the suppressor activity of anergic T cells. Taken together, our experiments demonstrate that anergic T cells induced by IL-10-treated DCs are able to suppress activation and function of T cells in an antigen-specific manner. Induction of anergic T cells might be exploited therapeutically for suppression of cellular immune responses in allergic or autoimmune diseases with identified (auto) antigens.

Citing Articles

Dysregulated dendritic cells in sepsis: functional impairment and regulated cell death.

Zheng L, Duan Y, He P, Wu M, Wei S, Du X Cell Mol Biol Lett. 2024; 29(1):81.

PMID: 38816685 PMC: 11140885. DOI: 10.1186/s11658-024-00602-9.


Helios as a Potential Biomarker in Systemic Lupus Erythematosus and New Therapies Based on Immunosuppressive Cells.

Paris-Munoz A, Leon-Triana O, Perez-Martinez A, Barber D Int J Mol Sci. 2024; 25(1).

PMID: 38203623 PMC: 10778776. DOI: 10.3390/ijms25010452.


Myeloid-derived suppressor cells in cancer and cancer therapy.

Lasser S, Ozbay Kurt F, Arkhypov I, Utikal J, Umansky V Nat Rev Clin Oncol. 2024; 21(2):147-164.

PMID: 38191922 DOI: 10.1038/s41571-023-00846-y.


Therapeutic induction of antigen-specific immune tolerance.

Kenison J, Stevens N, Quintana F Nat Rev Immunol. 2023; 24(5):338-357.

PMID: 38086932 PMC: 11145724. DOI: 10.1038/s41577-023-00970-x.


Therapeutic properties of Helicobacter pylori-derived vacuolating cytotoxin A in an animal model of chronic allergic airway disease.

Raspe J, Schmitz M, Barbet K, Caso G, Cover T, Muller A Respir Res. 2023; 24(1):178.

PMID: 37415170 PMC: 10324189. DOI: 10.1186/s12931-023-02484-5.